TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Japan Tissue Engineering Co., Ltd. ( (JP:7774) ) has provided an announcement.
Japan Tissue Engineering Co., Ltd. has released its financial report for the fiscal year ending March 2025, highlighting its business performance and topics for the year. The report includes an earnings forecast for the fiscal year ending March 2026, indicating the company’s strategic focus on advancing regenerative medical products and maintaining its position in the industry.
More about Japan Tissue Engineering Co., Ltd.
Japan Tissue Engineering Co., Ltd. operates in the regenerative medicine industry, focusing on the development and manufacturing of autologous cultured tissues. The company offers products such as JACE, JACEMIN, JACC, NEPIC, OCURAL, and LabCyte, which are used for various medical and research purposes.
Average Trading Volume: 300,762
Technical Sentiment Signal: Buy
Current Market Cap: Yen23.35B
See more insights into 7774 stock on TipRanks’ Stock Analysis page.